Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACLX Stock Forecast 2026-2027
$115.07
Current Price
$6.73B
Market Cap
Buy 0
Hold 14
Sell 0
Wall St Analyst Ratings
Distance to ACLX Price Targets
+4.3%
To High Target of $120.00
-0.1%
To Median Target of $115.00
-28.7%
To Low Target of $82.00
ACLX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+79.5%
1 Year Change
+76.5%
Year-to-Date Change
-0.1%
From 52W High of $115.13
+103.4%
From 52W Low of $56.58
📊 TOP ANALYST CALLS
Did ACLX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Arcellx is one of their latest high-conviction picks.
Latest ACLX Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, ACLX has a neutral consensus with a median price target of $115.00 (ranging from $82.00 to $120.00). The overall analyst rating is Buy (6.0/10). Currently trading at $115.07, the median forecast implies a -0.1% downside. This outlook is supported by 0 Buy, 14 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Asthika Goonewardene at Truist Securities, projecting a 4.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACLX Analyst Ratings
0
Buy
14
Hold
0
Sell
ACLX Price Target Range
Low
$82.00
Average
$115.00
High
$120.00
Current: $115.07
Latest ACLX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACLX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 26, 2026 | Guggenheim | Kelsey Goodwin | Neutral | Downgrade | $115.00 |
| Feb 24, 2026 | Truist Securities | Asthika Goonewardene | Hold | Downgrade | $120.00 |
| Feb 24, 2026 | Evercore ISI Group | Cory Kasimov | In-Line | Downgrade | $115.00 |
| Feb 24, 2026 | UBS | Michael Yee | Neutral | Downgrade | $115.00 |
| Feb 24, 2026 | Citigroup | Geoff Meacham | Neutral | Downgrade | $115.00 |
| Feb 24, 2026 | Leerink Partners | Daina Graybosch | Market Perform | Downgrade | $115.00 |
| Feb 24, 2026 | Stifel | Stephen Willey | Hold | Downgrade | $115.00 |
| Feb 23, 2026 | HC Wainwright & Co. | Emily Bodnar | Neutral | Downgrade | $115.00 |
| Feb 23, 2026 | Baird | Jack Allen | Neutral | Downgrade | $115.00 |
| Feb 23, 2026 | Needham | Gil Blum | Hold | Downgrade | $N/A |
| Feb 23, 2026 | Wells Fargo | Yanan Zhu | Equal-Weight | Downgrade | $115.00 |
| Feb 5, 2026 | Needham | Buy | Reiterates | $N/A | |
| Feb 4, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Assumes | $100.00 |
| Dec 22, 2025 | Wells Fargo | Overweight | Initiates | $N/A | |
| Dec 8, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 8, 2025 | Needham | Buy | Reiterates | $N/A | |
| Nov 18, 2025 | Wolfe Research | Peer Perform | Initiates | $N/A | |
| Nov 3, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Oct 16, 2025 | Stifel | Stephen Willey | Buy | Reinstates | $129.00 |
Arcellx, Inc. (ACLX) Competitors
The following stocks are similar to Arcellx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Arcellx, Inc. (ACLX) Financial Data
Valuation Metrics
Market Cap
$6.73B
Enterprise Value
$6.33B
P/E Ratio
N/A
PEG Ratio
-66.4x
Price/Sales
302.1x
Growth & Margins
Revenue Growth (YoY)
-89.2%
Gross Margin
N/A
Operating Margin
-3,850.2%
Net Margin
0.0%
EPS Growth
-89.2%
Financial Health
Cash/Price Ratio
+6.7%
Current Ratio
4.4x
Debt/Equity
12.9x
ROE
-53.4%
ROA
-24.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Arcellx, Inc. (ACLX) Business Model
About Arcellx, Inc.
What They Do
Develops innovative cell therapies for cancer.
Business Model
Arcellx operates as a clinical-stage biotechnology company, generating revenue through the development and commercialization of advanced cell therapies. It focuses on creating treatments leveraging proprietary platforms, such as ddCAR and ARC-SparX, for various cancer types, and may collaborate with larger pharmaceutical companies like Kite Pharma for co-development and commercialization.
Additional Information
The company is headquartered in Redwood City, California, and has been active since 2014. Its lead product candidate is in phase 3 clinical trials, indicating significant progress in the development pipeline. Arcellx aims to enhance safety and effectiveness in cancer treatment through its innovative therapeutic approaches.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
209
CEO
Mr. Rami Elghandour
Country
United States
IPO Year
N/A
Website
www.arcellx.comArcellx, Inc. (ACLX) Latest News & Analysis
Latest News
Quick Summary
Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have shown performance metrics relative to their sector in 2023. Further details on specific performance metrics were not provided.
Why It Matters
The performance comparison of Arcellx and Astellas Pharma against their sector reveals trends that may impact stock valuations and investor sentiment in the biotech industry.
Source: Zacks Investment Research
Market Sentiment:
Negative
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
1 month ago
Quick Summary
Gilead Sciences has completed its acquisition of Arcellx for $115 per share in cash, plus a $5 contingent value right, totaling an equity value of about $7.8 billion.
Why It Matters
Gilead's $7.8 billion acquisition of Arcellx enhances its portfolio in the biopharmaceutical sector, signaling growth potential and strategic expansion, which can impact stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
As of March 18, 2026, two healthcare stocks are signaling potential caution for momentum-focused investors.
Why It Matters
Momentum indicators for two health care stocks suggest potential downturns, signaling increased risk for investors relying on momentum strategies.
Source: Benzinga
Market Sentiment:
Negative
Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders
2 months ago
Quick Summary
Halper Sadeh LLC is investigating Kennedy-Wilson Holdings, Inc. (NYSE: KW) for potential federal securities law violations related to its $10.90 per share sale to a consortium led by executives.
Why It Matters
The investigation into Kennedy-Wilson's sale may indicate potential legal issues or undervaluation, impacting shareholder sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
2 months ago
Quick Summary
Cormorant Asset Management sold 775,000 shares of Arcellx in Q4, resulting in a $63.63 million decrease in its position value due to a complete sale.
Why It Matters
Cormorant Asset Management's complete exit from Arcellx signals a lack of confidence in the company's prospects, potentially impacting stock prices and investor sentiment.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Kahn Swick & Foti is investigating Arcellx's proposed sale to Gilead Sciences, offering $115 per share plus a $5 contingent value right, contingent on milestone achievements.
Why It Matters
The investigation into Arcellx's sale could impact the deal's final terms, affecting share price and investor returns, particularly regarding the contingent value rights.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ACLX Stock
What is Arcellx, Inc.'s (ACLX) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Arcellx, Inc. (ACLX) has a median price target of $115.00. The highest price target is $120.00 and the lowest is $82.00.
Is ACLX stock a good investment in 2026?
According to current analyst ratings, ACLX has 0 Buy ratings, 14 Hold ratings, and 0 Sell ratings. The stock is currently trading at $115.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACLX stock?
Wall Street analysts predict ACLX stock could reach $115.00 in the next 12 months. This represents a -0.1% decrease from the current price of $115.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arcellx, Inc.'s business model?
Arcellx operates as a clinical-stage biotechnology company, generating revenue through the development and commercialization of advanced cell therapies. It focuses on creating treatments leveraging proprietary platforms, such as ddCAR and ARC-SparX, for various cancer types, and may collaborate with larger pharmaceutical companies like Kite Pharma for co-development and commercialization.
What is the highest forecasted price for ACLX Arcellx, Inc.?
The highest price target for ACLX is $120.00 from Asthika Goonewardene at Truist Securities, which represents a 4.3% increase from the current price of $115.07.
What is the lowest forecasted price for ACLX Arcellx, Inc.?
The lowest price target for ACLX is $82.00 from at , which represents a -28.7% decrease from the current price of $115.07.
What is the overall ACLX consensus from analysts for Arcellx, Inc.?
The overall analyst consensus for ACLX is neutral. Out of 14 Wall Street analysts, 0 rate it as Buy, 14 as Hold, and 0 as Sell, with a median price target of $115.00.
How accurate are ACLX stock price projections?
Stock price projections, including those for Arcellx, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 12:10 AM UTC